Legal & General Group PLC Allogene Therapeutics, Inc. Transaction History

Legal & General Group PLC

$368 Billion
Q4 2024

A detailed history of Legal & General Group PLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 112,235 shares of ALLO stock, worth $228,959. This represents 0.0% of its overall portfolio holdings.

Number of Shares

112,235

Previous 127,407 11.91%

Holding current value

$228,959

Previous $356,000 32.87%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$1.84 - $3.22 $27,916 - $48,853	-15,172 Reduced 11.91%	112,235 $239,000
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $3,251 - $5,470	1,563 Added 1.24%	127,407 $356,000
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $69,089 - $135,701	30,982 Added 32.66%	125,844 $293,000
Q1 2024 Jul 01, 2024	BUY	$2.92 - $5.63 $5,042 - $9,723	1,727 Added 1.85%	94,862 $424,000
Q1 2024 May 14, 2024	BUY	$2.92 - $5.63 $32,058 - $61,811	10,979 Added 13.36%	93,135 $416,000
Q4 2023 Feb 15, 2024	BUY	$2.28 - $3.5 $1,931 - $2,964	847 Added 1.04%	82,156 $263,000
Q3 2023 Nov 14, 2023	BUY	$3.17 - $5.96 $13,006 - $24,453	4,103 Added 5.31%	81,309 $257,000
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $13,195 - $22,019	2,682 Added 3.6%	77,206 $381,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $7,766 - $15,354	1,382 Added 1.89%	74,524 $468,000
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $23,013 - $38,534	-2,230 Reduced 2.96%	73,142 $790,000
Q2 2022 Aug 22, 2022	BUY	$6.78 - $12.28 $89,706 - $162,476	13,231 Added 21.29%	75,372 $859,000
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $856 - $1,712	112 Added 0.18%	62,141 $566,000
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $530,733 - $698,214	25,261 Added 68.7%	62,029 $1.59 Million
Q2 2021 Aug 12, 2021	SELL	$23.49 - $35.8 $11,698 - $17,828	-498 Reduced 1.34%	36,768 $959,000
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $258,905 - $391,721	10,039 Added 36.87%	37,266 $1.32 Million
Q4 2020 Feb 12, 2021	SELL	$25.24 - $43.45 $1,312 - $2,259	-52 Reduced 0.19%	27,227 $687,000
Q3 2020 Nov 13, 2020	SELL	$32.38 - $44.96 $48,019 - $66,675	-1,483 Reduced 5.16%	27,279 $1.03 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $60,484 - $177,737	3,289 Added 12.91%	28,762 $1.23 Million
Q1 2020 May 14, 2020	SELL	$18.22 - $28.25 $31,028 - $48,109	-1,703 Reduced 6.27%	25,473 $496,000
Q4 2019 Feb 13, 2020	BUY	$24.82 - $31.4 $191,833 - $242,690	7,729 Added 39.74%	27,176 $706,000
Q2 2019 Aug 14, 2019	SELL	$25.56 - $31.09 $2.11 Million - $2.57 Million	-82,583 Reduced 80.94%	19,447 $522,000
Q1 2019 May 15, 2019	BUY	$24.82 - $32.54 $2.45 Million - $3.21 Million	98,721 Added 2983.41%	102,030 $2.95 Million
Q4 2018 Feb 15, 2019	BUY	$22.5 - $33.3 $74,452 - $110,189	3,309 New	3,309 $89,000

Others Institutions Holding ALLO

# of Institutions

178

Shares Held

143M

Call Options Held

37.5K

Put Options Held

77.8K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $293M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Allogene Therapeutics, Inc. Transaction History